loading...| Preferred Name |
alvimopan |
|
| Synonyms |
Entereg |
|
| Definitions |
A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons andthe immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opiod-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49096" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49096" NCI Thesaurus) |
|
| ID |
http://purl.bioontology.org/ontology/PDQ/CDR0000453551 |
|
| altLabel |
Entereg ADL8-2698 LY-246376 |
|
| cui |
C1508750 C1508751 C0963856 C1706785 |
|
| DATE FIRST PUBLISHED |
2005-10-24 |
|
| Date last modified |
2006-07-26 |
|
| definition |
A synthetic trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine with peripherally selective opioid mu receptor antagonist activity. Alvimopan is a selective and competitive antagonist at mu-opioid receptors, found in myenteric and submucosal neurons andthe immune cells of the lamina propria in the human gut. Upon administration, this agent binds to mu-opioid receptors in the gut, thereby reversing opiod-related disturbances in gut motility. Alvimopan is approximately three to nine times more potent than naloxone. Check for "https://www.cancer.gov/about-cancer/treatment/clinical-trials/intervention/C49096" active clinical trials using this agent. ("http://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI%20Thesaurus&code=C49096" NCI Thesaurus) |
|
| LT |
TRD |
|
| NCI ID |
C49096 |
|
| notation |
CDR0000453551 |
|
| ORIG STY |
Drug/agent |
|
| prefLabel |
alvimopan |
|
| tui |
T109 T121 |